These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12529298)

  • 1. Polymorphic expression of CD158k/p140/KIR3DL2 in Sézary patients.
    Musette P; Michel L; Jean-Louis F; Bagot M; Bensussan A
    Blood; 2003 Feb; 101(3):1203. PubMed ID: 12529298
    [No Abstract]   [Full Text] [Related]  

  • 2. Significance of circulating T-cell clones in Sezary syndrome.
    Ortonne N; Huet D; Gaudez C; Marie-Cardine A; Schiavon V; Bagot M; Musette P; Bensussan A
    Blood; 2006 May; 107(10):4030-8. PubMed ID: 16418328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome.
    Poszepczynska-Guigné E; Schiavon V; D'Incan M; Echchakir H; Musette P; Ortonne N; Boumsell L; Moretta A; Bensussan A; Bagot M
    J Invest Dermatol; 2004 Mar; 122(3):820-3. PubMed ID: 15086570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD158k/KIR3DL2 is a useful marker for identifying neoplastic T-cells in Sézary syndrome by flow cytometry.
    Bahler DW; Hartung L; Hill S; Bowen GM; Vonderheid EC
    Cytometry B Clin Cytom; 2008 May; 74(3):156-62. PubMed ID: 18061949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional and molecular characterization of a KIR3DL2/p140 expressing tumor-specific cytotoxic T lymphocyte clone infiltrating a human lung carcinoma.
    Dorothée G; Echchakir H; Le Maux Chansac B; Vergnon I; El Hage F; Moretta A; Bensussan A; Chouaib S; Mami-Chouaib F
    Oncogene; 2003 Oct; 22(46):7192-8. PubMed ID: 14562047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of PLS3, Twist, CD158k/KIR3DL2, and NKp46 gene expression combination for reliable Sézary syndrome diagnosis.
    Michel L; Jean-Louis F; Begue E; Bensussan A; Bagot M
    Blood; 2013 Feb; 121(8):1477-8. PubMed ID: 23429988
    [No Abstract]   [Full Text] [Related]  

  • 7. Engagement of ILT2/CD85j in Sézary syndrome cells inhibits their CD3/TCR signaling.
    Nikolova M; Musette P; Bagot M; Boumsell L; Bensussan A
    Blood; 2002 Aug; 100(3):1019-25. PubMed ID: 12130517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD158K/KIR3DL2 transcript detection in lesional skin of patients with erythroderma is a tool for the diagnosis of Sézary syndrome.
    Ortonne N; Le Gouvello S; Mansour H; Poillet C; Martin N; Delfau-Larue MH; Leroy K; Farcet JP; Bagot M; Bensussan A
    J Invest Dermatol; 2008 Feb; 128(2):465-72. PubMed ID: 17703174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Killer cell immunoglobulin-like receptor expression delineates in situ Sézary syndrome lymphocytes.
    Wechsler J; Bagot M; Nikolova M; Parolini S; Martin-Garcia N; Boumsell L; Moretta A; Bensussan A
    J Pathol; 2003 Jan; 199(1):77-83. PubMed ID: 12474229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD158k/KIR3DL2 and NKp46 are frequently expressed in transformed mycosis fungoides.
    Ortonne N; Le Gouvello S; Tabak R; Marie-Cardine A; Setiao J; Berrehar F; Nghe-Tang A; Martin N; Bagot M; Bensussan A
    Exp Dermatol; 2012 Jun; 21(6):461-3. PubMed ID: 22621189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Epidermotropic T cell lymphomas as models for tumor progression].
    Bagot M; Bensussan A
    Med Sci (Paris); 2006 Feb; 22(2):192-6. PubMed ID: 16457762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD158k and PD-1 expressions define heterogeneous subtypes of Sezary syndrome.
    Vergnolle I; Douat-Beyries C; Boulinguez S; Rieu JB; Vial JP; Baracou R; Boudot S; Cazeneuve A; Chaugne S; Durand M; Estival S; Lablanche N; Nicolau-Travers ML; Tournier E; Lamant L; Vergez F
    Blood Adv; 2022 Mar; 6(6):1813-1825. PubMed ID: 34570200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absolute CD3+ CD158k+ lymphocyte count is reliable and more sensitive than cytomorphology to evaluate blood tumour burden in Sézary syndrome.
    Bouaziz JD; Remtoula N; Bensussan A; Marie-Cardine A; Bagot M
    Br J Dermatol; 2010 Jan; 162(1):123-8. PubMed ID: 19681856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of killer cell immunoglobulin-like receptors gene KIR3DL2 diversity and confirmation of KIR3DL2*015 in a Chinese population.
    Yan LX; Zhu FM; Jiang K; Lv QF; He JJ
    Tissue Antigens; 2006 Sep; 68(3):220-4. PubMed ID: 16948642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of killer cell immunoglobulin-like receptor gene diversity V. KIR3DL2.
    Meenagh A; Williams F; Sleator C; Halfpenny IA; Middleton D
    Tissue Antigens; 2004 Sep; 64(3):226-34. PubMed ID: 15304002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors.
    Leung W; Iyengar R; Triplett B; Turner V; Behm FG; Holladay MS; Houston J; Handgretinger R
    J Immunol; 2005 May; 174(10):6540-5. PubMed ID: 15879158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diversity of killer cell immunoglobulin-like receptor genes in Pacific Islands populations.
    Velickovic M; Velickovic Z; Dunckley H
    Immunogenetics; 2006 Jul; 58(7):523-32. PubMed ID: 16733717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of interleukin IL-2 and IL-12 + IL-18 on surface expression of immunoglobulin-like receptors KIR2DL1, KIR2DL2, and KIR3DL2 in natural killer cells.
    Chrul S; Polakowska E; Szadkowska A; Bodalski J
    Mediators Inflamm; 2006; 2006(4):46957. PubMed ID: 17047292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KIR3DL2 is a coinhibitory receptor on Sézary syndrome malignant T cells that promotes resistance to activation-induced cell death.
    Thonnart N; Caudron A; Legaz I; Bagot M; Bensussan A; Marie-Cardine A
    Blood; 2014 Nov; 124(22):3330-2. PubMed ID: 25414436
    [No Abstract]   [Full Text] [Related]  

  • 20. CD158k is a reliable marker for diagnosis of Sézary syndrome and reveals an unprecedented heterogeneity of circulating malignant cells.
    Moins-Teisserenc H; Daubord M; Clave E; Douay C; Félix J; Marie-Cardine A; Ram-Wolff C; Maki G; Beldjord K; Homyrda L; Michel L; Bensussan A; Toubert A; Bagot M
    J Invest Dermatol; 2015 Jan; 135(1):247-257. PubMed ID: 25158034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.